Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Exelixis (EXEL) Tops Q4 Earnings Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 46.67% and -0.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.
Exelixis (EXEL) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Exelixis (EXEL) closed at $17.60, marking a +0.69% move from the previous day.
Roche Submits Application for Tecentriq-Avastin Combo in HCC
by Zacks Equity Research
Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
GILD or EXEL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. EXEL: Which Stock Is the Better Value Option?
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study
by Zacks Equity Research
Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data
by Zacks Equity Research
A low-key week for the biotech sector, with a few pipeline and regulatory updates.
Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study
by Zacks Equity Research
Roche's (RHHBY) Tecentriq in combination with Cotellic and Zelboraf meets primary goal.
Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 55.00% and 18.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q3 results.
Earnings Preview: Exelixis (EXEL) Q3 Earnings Expected to Decline
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study
by Zacks Equity Research
Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.
Seattle Genetics Up on Positive Data From Bladder Cancer Study
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.
Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.
Renal Cell Carcinoma Space in Focus: Some Key Developments
by Ekta Bagri
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.
Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.
Exelixis (EXEL) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 8.70% and 5.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.